RANDOMIZED PHASE II CLINICAL TRIAL OF TAILORED IRINOTECAN (CPT-11) PLUS S-1 VERSUS S-1 IN PATIENTS WITH ADVANCED OR RECURRENT GASTRIC CARCINOMA AS THE FIRST-LINE CHEMOTHERAPY (THE JAPANESE FOUNDATION FOR MULTIDISCIPLINARY TREATMENT OF CANCER, JFMC31-0301)

被引：0
|
作者：
Takahashi, Y. [1 ]
Komatsu, Y. [2 ]
Kitajima, M. [3 ]
Kubota, T. [4 ]
Saji, S. [5 ]
Nishiyama, M. [6 ]
Kimura, Y. [7 ]
Oda, H. [8 ]
Tajima, Y. [9 ]
Miki, H. [10 ]
机构：
[1] Chiba Univ, Chiba, Japan
[2] Hokkaido Univ Hosp, Ctr Canc, Sapporo, Hokkaido 060, Japan
[3] Int Univ Hlth & WelfareS, Tokyo, Japan
[4] Keio Univ, Ctr Comprehens & Adv Med, Tokyo, Japan
[5] Japanese Fdn Multidisciplinary Treatment Canc, Tokyo, Japan
[6] Saitma Med Univ, Int Med Ctr, Translat Tesearch Ctr, Hidaka, Saitama, Japan
[7] NTT W Osaka Hosp, Osaka, Japan
[8] Kushiro Rosai Hosp, Kushiro, Hokkaido, Japan
[9] Showa Univ, Sch Med, Tokyo 142, Japan
[10] Kansai Rosai Hosp, Amagasaki, Hyogo, Japan
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：172 / 172
页数：1
相关论文
共 50 条
  • [41] Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer
    Tsunoda, A.
    Yasuda, N.
    Nakao, K.
    Narita, K.
    Yamazaki, K.
    Watanabe, M.
    Suzuki, N.
    Kusano, M.
    ONCOLOGY, 2007, 72 (1-2) : 58 - 63
  • [42] Phase II study of S-1 in combination with paclitaxel as a first-line treatment for patients with advanced/recurrent gastric cancer
    Toh, U.
    Yamana, H.
    Koufuji, K.
    Mine, T.
    Aoyagi, K.
    Miyagi, M.
    Imaizumi, T.
    Shirouzu, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] A randomized phase II factorial design trial of CPT-11 versus PTX versus each combination with S-1 in patients with advanced gastric cancer refractory to S-1: Final results of OGSG0701.
    Nishikawa, Kazuhiro
    Imamura, Hiroshi
    Kawase, Tomono
    Gotoh, Masahiro
    Kimura, Yutaka
    Ueda, Shugo
    Matsuyama, Jin
    Kawada, Junji
    Sugimoto, Naotoshi
    Fujita, Junya
    Tamura, Takao
    Fukushima, Norimasa
    Sakai, Daisuke
    Shimokawa, Toshio
    Kurokawa, Yukinori
    Satoh, Taroh
    Tsujinaka, Toshimasa
    Furukawa, Hiroshi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [44] Nab-paclitaxel plus S-1 versus oxaliplatin plus S-1 as first-line treatment in advanced gastric cancer: results of a multicenter, randomized, phase III trial (GAPSO study)
    Dai, Yu-Hong
    Yu, Xiong-Jie
    Xu, Hui-Ting
    Zhuang, Liang
    Zhang, Ming-Sheng
    Zou, Yan-Mei
    Fu, Qiang
    Qiu, Hong
    Yuan, Xiang-Lin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [45] A randomized multicenter phase II trial of capecitabine versus S-1 as first-line treatment in unresectable or recurrent breast cancer patients
    Yamamoto, D.
    Iwase, S.
    Odagiri, H.
    Kuroda, Y.
    Akazawa, K.
    Kitamura, K.
    Kawaguchi, T.
    Yamamoto, C.
    Nagumo, Y.
    Sakata, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05)
    Tanabe, K.
    Fujii, M.
    Nishikawa, K.
    Kunisaki, C.
    Tsuji, A.
    Matsuhashi, N.
    Takagane, A.
    Ohno, T.
    Kawase, T.
    Kochi, M.
    Yoshida, K.
    Kakeji, Y.
    Ichikawa, W.
    Chin, K.
    Terashima, M.
    Takeuchi, M.
    Nakajima, T.
    ANNALS OF ONCOLOGY, 2015, 26 (09) : 1916 - 1922
  • [47] Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer
    Mizuno, Nobumasa
    Yamao, Kenji
    Komatsu, Yoshito
    Munakata, Masaki
    Ishiguro, Atsushi
    Yamaguchi, Taketo
    Ohkawa, Shinichi
    Kida, Mitsuhiro
    Ioka, Tatsuya
    Takeda, Koji
    Kudo, Toshihiro
    Kitano, Masayuki
    Iguchi, Haruo
    Tsuji, Akihito
    Ito, Tetsuhide
    Tanaka, Masao
    Furuse, Junji
    Hamada, Chikuma
    Sakata, Yuh
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [48] Phase II study of S-1 in combination with irinotecan (CPT-11) for patients with advanced/recurrent breast cancer (KSCOG-BC01)
    Toh, U.
    Fukushima, T.
    Fukunaga, M.
    Iwakuma, N.
    Takenaka, M.
    Otsuka, H.
    Shirouzu, K.
    Ogo, E.
    EJC SUPPLEMENTS, 2010, 8 (03): : 204 - 204
  • [49] A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer
    Manabu Shiozawa
    Nobuhiro Sugano
    Kazuhito Tsuchida
    Soichiro Morinaga
    Makoto Akaike
    Yukio Sugimasa
    Journal of Cancer Research and Clinical Oncology, 2009, 135 : 365 - 370
  • [50] A PHASE II CLINICAL TRIAL OF PACLITAXEL/CISPLATIN/S-1 TRIPLET COMBINATION CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER AS FIRST-LINE THERAPY
    Song, H. S.
    Do, Y. R.
    Lee, W. S.
    Kim, J. G.
    Chae, Y. S.
    Lee, K. H.
    Kim, M. K.
    Rhoo, H.
    Park, K.
    Baek, J. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 173 - 173
12345